Abstract

Anti-retroviral treatment enhances the immune status and reduces unwanted outcomes. However, development of treatment failure and drug resistance raises concern over lifelong treatments to chronic diseases such as HIV/AIDS. This study determined proportion of treatment failure (TF) and identified factors associated with TF among people living with human immunodeficiency virus (HIV) in Bahir Dar, Northwest Ethiopia. Facility based cross sectional study was carried out from November, 2017 to April, 2018. Sociodemographic and clinical data were collected using structured questioner. Blood sample was collected and analyzed for viral load, complete blood count (CBC), liver and kidney function test and CD4 count. A patient is declared as treatment failure when viral load value is higher than 1000 RNA copies/ml in two consecutive viral load analyses within three months interval. Data were entered and analyzed using SPSS version 23. To identify factors associated with TF, logistic regressions model was employed. A total of 430 people who had six months and above antiretroviral treatment (ART) follow up were enrolled in the study. Of these, 57.9% were females & the mean age was 38 years. The mean month of ART follow up was 83 months. In the first viral load analysis, 106 (24.7%) of the cohort were virologically failed. These failed people were followed for 3 months with intensive adherence support; then second viral load analysis showed a viralogical failure among 65 people of the second cohort. Thus, the overall viralogical failure or TF was 15.1%. The re-suppression rates were 41(38.7%). Male gender, people with history of drug discontinuation, poor adherence, irregular time of drug intake, multiple sexual practice showed significant association with TF. Moreover, base line and current CD4 counts of <200 cells/ml also demonstrated significant association with TF. Significant proportion of treatment failure was reported in the present study. Moreover, behavioral factors such as drug discontinuation, poor adherence, multiple sexual partner were associated with treatment failure. Hence, to avoid TF, regular patient counseling and monitoring should be in place. To identify the predictors for treatment failure, further follow-up study is desirable.

Highlights

  • Anti-retroviral treatment enhances the immune status and reduces unwanted outcomes

  • Based on single plasma viral load (PVL) study, Study population All people living with human immunodeficiency virus (HIV) (PLWHIV) in Bahir Dar city administration were the source population and those who attended antiretroviral treatment (ART) follow up at the three health facilities during the study period were the study population

  • TB/HIV co-infection and months of treatment did not show association with treatment failure (TF). This finding was corroborated with report in Cameron 40. These results indicate that irregular time of medication, drug discontinuation, poor adherence, multiple sexual history, male gender, baseline and current CD4 count

Read more

Summary

Introduction

Anti-retroviral treatment enhances the immune status and reduces unwanted outcomes. development of treatment failure and drug resistance raises concern over lifelong treatments to chronic diseases such as HIV/AIDS. Objectives: This study determined proportion of treatment failure (TF) and identified factors associated with TF among people living with human immunodeficiency virus (HIV) in Bahir Dar, Northwest Ethiopia. Results: A total of 430 people who had six months and above antiretroviral treatment (ART) follow up were enrolled in the study. Conclusion: Significant proportion of treatment failure was reported in the present study. Behavioral factors such as drug discontinuation, poor adherence, multiple sexual partner were associated with treatment failure. First line antiretroviral treatment failure and associated factors among people living with HIV in northwest Ethiopia. Based on World Health Organization (WHO) report of 2015, 36.7 million people were living with HIV.

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.